At the beginning of the Chinese New Year, Sciwind completed Series A financing of approximately 200 million RMB (29.5 million US dollars) led by Legend Capital and followed by pre-A investor Shiyu Cap
Fight to fatty hepatitis, liver fibrosis and cirrhosis！
Hangzhou Sciwind Biosciences Co.,Ltd establish, and unveil its BeiJing R&D Center.
On Sep 30, 2017， We Introduce two strategic investment partners: ShiYu Capital and HaiBang Venture, financing 60 million.
On Aug 17, 2017，Our company register in Hangzhou, 2 million registered capital.